The optimal management of locally advanced, Stage IIIA NSCLC with N2 level nodal metastases remains challenging and controversial. A number of treatment regimens have been shown safe and effective, but existing clinical trial data frequently falls short of providing guidance to match the right approach with the right patient. We review recent literature in this area and its impact.